About this trial
The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored. The purpose of this study is to directly asses the mechanistic role of inflammation in this dysfunction.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
18 - 24 years of age
no history of e-cigarette use (control) OR current with 6 months or more history of e-cigarette use (chronic use).
Disqualifiers
tobacco cigarette use (current or history of)
use of stimulant drugs
skin diseases
cardiovascular disease
Trial design
Crossover
Treatments tested in this trial
Placebo
DrugOral placebo tablet
Salsalate 750 MG Oral Tablet [DISALCID]
DrugOral salsalate tablet
Treatment groups
Trial outcomes
Primary outcomes
Microvascular endothelial function (Cutaneous conductance, %maximum) following salsalate treatment compared to placebo treatment
Endothelium-dependent vasodilation assessed as cutaneous conductance response (cutaneous conductance = local red blood cell flux/mean arterial pressure; %maximum) to local heating of the skin (42 degrees Celcius).
Sponsors and contacts
Click on the lead sponsor to view all of their trials.